Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–7.

Article  PubMed  Google Scholar 

Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34:381–90.

Article  PubMed  PubMed Central  Google Scholar 

Leoncini G, Viazzi F, Agabiti-Rosei E, Ambrosioni E, Costa FV, Leonetti G, Pessina A, Trimarco B, Volpe M, Deferrari G, Pontremoli R. Chronic kidney disease in the hypertensive patient. High Blood Press Cardiovasc Prev. 2011;18:31–6.

Article  PubMed  Google Scholar 

Johansen KL, Chertow GM, Gilbetrtson DT, Ishani A, Israni A, Ku E, Li S, Liu J, Obrador GT, Schulman I, Chan K, Abbot KC, O’Hare AM, Powe NR, Roetker NS, Scherer JS, Peter WS, Snyder J, Winkelmayer WC, Wong SPY, Wetmore JB. US renal data system 2022 annual data report. Am J Kid Dis. 2023;81(Suppl 1):A8–11.

Article  PubMed  Google Scholar 

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019;74:120–31.

Article  PubMed  Google Scholar 

Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341–5.

Article  CAS  PubMed  Google Scholar 

Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and non-resistant hypertension. Kidney Int. 2015;88:622–32.

Article  PubMed  PubMed Central  Google Scholar 

Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities’ study. J Am Soc Nephrol. 2005;16:529–38.

Article  PubMed  Google Scholar 

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya N. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the hypertension and the kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32:620–40.

Article  PubMed  Google Scholar 

Quarti-Trevano F, Seravalle G, Dell’Oro R, Mancia G, Grassi G. Autonomic cardiovascular alterations in chronic kidney disease; effects of dialysis, kidney transplantation and renal denervation. Curr Hypertens Rep. 2021;23:10.

Article  PubMed  PubMed Central  Google Scholar 

Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.

Article  PubMed  Google Scholar 

Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell’Oro R, Mancia G. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.

Article  CAS  PubMed  Google Scholar 

Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20:933–9.

Article  PubMed  Google Scholar 

Mazza A, Dell’Avvocata F, Torin G, Bulighin F, Battaglia Y, Fiorini F. Does renal denervation a reasonable treatment option in hemodialysis-dependent patients with resistant hypertension? A narrative review. Curr Hypertens Rep. 2023;25:353–63.

Article  PubMed  PubMed Central  Google Scholar 

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41:1874–2071.

Article  CAS  PubMed  Google Scholar 

Dell’Oro R, Quarti-Trevano F, Seravalle G, Bertoli S, Airoldi F, Mancia G, Grassi G. Sympathetic nerve traffic and arterial baroreflex function in apparent drug-resistant hypertension. Hypertension. 2019;74:903–9.

Article  PubMed  Google Scholar 

Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER III. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016;67:387–96.

Article  CAS  PubMed  Google Scholar 

de Beus E, van der Sande NGC, Bots ML, Spiering W, Voskuil M, Visseren FLJ, Blankestijn PJ. Prevalence and clinical characteristics of apparent therapy-resistant hypertension in patients with cardiovascular disease: a cross-sectional cohort study in secondary care. BMJ Open. 2017;7: e016692.

Article  PubMed  PubMed Central  Google Scholar 

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, ALLHAT Collaborative Research Group. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2014;64:1012–21.

Zoccali C, Moissl U, Chazot C, Mallamaci F, Tripepi G, Arkossy O, Wabel P, Stuard S. Chronic fluid overload and mortality in ESRD. J Am Soc Nephrol. 2017;28:2491–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seravalle G, Mancia G, Grassi G. Role of the sympathetic nervous system in hypertension and hypertension-related cardiovascular disease. High Blood Press Cardiovasc Prev. 2014;21:89–105.

Article  CAS  PubMed  Google Scholar 

Rubinger D, Backenroth R, Sapoznikov D. Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin Dial. 2013;26:333–43.

Article  PubMed  Google Scholar 

Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ Arrhythm Electrophysiol. 2010;3:553–9.

Article  PubMed  Google Scholar 

Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–9.

Article  CAS  PubMed  Google Scholar 

Bruno RM, Taddei S, Borghi C, Colivicchi F, Desideri G, Grassi G, Mazza A, Muiesan ML, Parati G, Pontremoli R, Trimarco B, Volpe M, Ferri C. Italian Society of Hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev. 2020;27:109–17.

Article  PubMed  Google Scholar 

Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, SPYRAL HTN-OFF MED Trial Investigators. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160–70.

Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, SPYRAL HTN-ON MED Trial Investigators. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346–55.

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, RADIANCE-HTN Investigators. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335–45.

Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444–51.

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, basile J, Bloch MJ, Daemen J, Lobo MD, Mafhoud F, Schmieer R, Sharp ASP, Weber MA Sapoval M, Fong P, RADIANCE-HTN Investigators, Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476–86.

Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, Kario K, Kroon AA, Lobo MD, Ott C, Patack A, Persu A, Scalise F, Schlaoch M, Kreutz R, Tsioufis C. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733–41.

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022;400:1405–16.

Schlaich MP, Sobotka PA, Krum H, Whitbourn R, Walton A, Esler MD. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension. 2009;54:1195–201.

Article  CAS  PubMed  Google Scholar 

Grassi G, Seravalle G, Brambilla G, Pini C, Trabattoni D, Cuspidi C, Corso R, Pieruzzi F, Genovesi S, Stella A, Facchetti R, Spaziani D, Bartorelli A, Mancia G. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension. 2015;65:1209–16.

Article  CAS  PubMed  Google Scholar 

Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61:457–64.

Article  CAS  PubMed  Google Scholar 

Biffi A, Dell’Oro R, Quarti-Trevano F, Cuspidi C, Corrao G, Mancia G, Grassi G. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension. 2023;80:659–67.

Article  CAS  PubMed  Google Scholar 

Sata Y, Schlaich MP. The potential role of catheter-based renal sympathetic denervation in chronic and end-stage kidney disease. J Cardiovasc Pharmacol Ther. 2016;21:344–52.

Article  CAS  PubMed  Google Scholar 

Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–9.

Article  PubMed  Google Scholar 

Aldiabat M, Alabdallah K, Kofahi A, Aziz S. Bilateral nephrectomy, the forgotten measure in the treatment of refractory hypertension in patients with end-stage renal disease: a case report and literature review. Cureus. 2020;12: e9031.

PubMed  PubMed Central  Google Scholar